Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Artificial liver device tested in humans for first time

NCT ID NCT06285253

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a device called miroliverELAP, which uses a bioengineered liver graft to filter blood outside the body, in 10 adults with acute liver failure. The goal was to check safety and see if it can support the liver for up to 48 hours, giving time for recovery or a transplant. Results are not yet available, but the study is complete.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bioengineered liver graft (miroliverELAP)
What this could lead to
If successful, this device could provide temporary liver support for patients with acute liver failure, giving the liver time to heal or bridging to a transplant.
What could go wrong
This is a very early phase 1 trial with only 10 participants, focused on safety. The device may not work as hoped, and there are risks of serious side effects from the blood-circulation procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

10 people

The number who actually took part.

Started

Oct 2024

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. 18 years to 80 years old at the time of signing the informed consent 2. Subject must: 1. be deemed competent to consent by an independent qualified practitioner, or 2. have consent given by a Legally Authorized Representative 3. Subject should be in the intensive care unit 4. Be diagnosed with 4.1. Acute Liver Failure defined as: 1. INR ≥ 2.0, and 2. Hepatic Encephalopathy Grade II-III (West Haven Criteria), and 3. Less than 4 weeks (28 days) of disease duration 4.2. Severe Acute Alcohol-Associated Hepatitis as defined as: <!-- --> 1. Hepatic Encephalopathy Grade I-III (West Haven Criteria), and 2. Model for End-Stage Liver Disease (MELD) Score ≥ 20, and 3. INR ≥ 2.0, and 4. No overt evidence of cirrhosis 4.3. Acute on Chronic Liver Failure: <!-- --> 1. Hepatic Encephalopathy Grade I-III (West Haven Criteria), and 2. Model for End-Stage Liver Disease (MELD) Score ≥ 20, and 3. INR ≥ 2.0, 5\. Subject is not a candidate for liver transplant and will not become a candidate in the event of worsening conditions. Exclusion Criteria 1. Grade IV West Haven Encephalopathy Criteria 2. Previous liver transplant 3. Currently requires chronic hemodialysis (CRRT or other forms of continuous renal replacement are allowed). 4. Uncontrolled documented infection, hypotension, or refractory shock. This is defined as a need for a single vasopressor, or combination of vasopressors, that exceed a norepinephrine equivalent of 0.5 mcg/kg/min. 5. Liver injury due to trauma 6. Any current liver cancer 7. Currently on medications with a narrow therapeutic index 8. Platelet count \< 40,000 μL 9. If the subject is intubated and has an acute lung injury 10. Experiencing a bleeding event, defined as: 1. Active gastrointestinal or other overt bleeding event, or 2. Hemoglobin drop \> 3g/dL within the past 24 hours, or 3. Received ≥ 3 units of red blood cell transfusion within the past 24 hours 11. Female that is currently pregnant, planning to be pregnant, or currently breastfeeding 12. Refusal to receive blood products

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute alcoholic hepatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cleveland Clinic Foundation

    Cleveland, Ohio, 44195, United States

  • Intermountain Healthcare

    Salt Lake City, Utah, 84103, United States

  • Mayo Clinic

    Rochester, Minnesota, 55902, United States

  • Mount Sinai Recanati/Miller Transplantation Institute

    New York, New York, 10029, United States

  • Northwestern Memorial Hospital

    Chicago, Illinois, 60611, United States

  • University of Michigan Medical School

    Ann Arbor, Michigan, 48109, United States

  • University of Minnesota Medical School

    Minneapolis, Minnesota, 55455, United States

  • Virginia Commonwealth University Medical Center

    Richmond, Virginia, 23970, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.